Jefferson Health First in South Jersey Region to Offer FDA-Approved Automated Breast Ultrasound System for Better Detection of Breast Cancer
Jefferson Health New Jersey is now offering a new FDA-approved Automated Breast Ultrasound System (ABUS) for the detection of breast cancer in women with dense breast tissue. This system has been clinically proven to increase breast cancer detection by more than 35 percent.
Jefferson is the first health system in southern New Jersey (south of Trenton) to offer this new FDA-approved technology.
The GE Healthcare Invenia™ ABUS, or Automated Breast Ultrasound System, is the only FDA-approved ultrasound supplemental breast screening technology specifically designed for detecting cancer in dense breasts. When used in addition to mammography, studies have shown that Invenia ABUS can improve breast cancer detection by 35.7 percent over mammography alone.
According to the National Cancer Institute, nearly half of all women age 40 and older who get mammograms are found to have dense breasts.Both cancer and dense breast tissue appear white on a mammogram, meaning in dense breasts, cancers may be masked on traditional mammography.
Studies have shown that women at the high end of the breast density spectrum (>75%) have a 10-year breast cancer risk 4 to 6 times greater than that of same-age women at the low end (<10%). For patients with dense breasts, ABUS, along with mammography, can greatly enhance the ability to detect cancer.
“We are excited to add this technology to our comprehensive breast cancer screening program,” said Dr. Kay Yoon Flannery, Medical Director of the Comprehensive Breast Center at the Sidney Kimmel Cancer Center in Washington Township. “By offering Automated Breast Ultrasound System, along with digital mammography for patients with dense breasts, we anticipate improving detection for small cancers that might be harder to detect with mammography alone.”
The American Cancer Society recommends women receive yearly mammograms beginning at age 40. If they have been informed that they have dense breast tissue, they should talk to their doctor about their specific risk and whether or not the ABUS system might be appropriate as an additional screening tool.